Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria
Blood (2020) 136 (Supplement 1): 35–37.
Currently there are no citedby results. Try again later.
